New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, HALO, CRIS, ING, AMGN, SINA, EXAS, PRAN, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
11:18 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
11:05 EDTEXASExact Sciences jumps after CMS agrees to cover cancer test
Subscribe for More Information
09:13 EDTINGEBA says EU stress test results to be published October 26
Subscribe for More Information
09:00 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:50 EDTEXASExact Sciences to see significant short squeeze on CMS decision, says Canaccord
Subscribe for More Information
07:32 EDTEXASExact Sciences price target raised to $27 from $20 at Jefferies
Subscribe for More Information
07:16 EDTEXASExact Sciences CMS decision a 'major positive' for shares, says Mizuho
Subscribe for More Information
07:12 EDTEXASExact Sciences price target raised to $34 from $28 at JMP Securities
JMP Securities increased its price target on Exact Sciences after CMS stated that the company's colorectal screening tool would be covered by Medicare and granted the company's request to price the test at $502. The firm thinks Cologuard will become the standard of care for the detection of colorectal cancer. It reiterates an Outperform rating on the stock. .
October 9, 2014
18:47 EDTEXASOn The Fly: After Hours Movers
UP AFTER EARNINGS: Helen of Troy (HELE), up 3%... Barracuda Networks (CUDA), up marginally after reporting second quarter results. ALSO HIGHER: Sucampo Pharmaceuticals (SCMP), up 19.2% after announcing settlement agreement resolving patent litigation on AMITIZA... Civeo (CVEO), up 15% after Greenlight Capital reported a 9.99% stake in the company... EXCO Resources (XCO), up 10.6% after T. Boone Pickens says that company approached by buyers, reported by Bloomberg... EXACT Sciences (EXAS), up 3.7% after announcing final national coverage determination for Cologuard... US Ecology (ECOL), up 2.5% following announcement that it will replace Measurement Specialties (MEAS) in S&P 600. DOWN AFTER EARNINGS: Procera Networks (PKT), down 19.3%... Sizmek (SZMK), down 13.9% following third quarter revenue guidance... VOXX International (VOXX), down 12.5%... Knowles (KN), down 8.1% after lowering third quarter guidance... Microchip (MCHP), down 8.2% after lowering second quarter guidance... Juniper Networks (JNPR), down 3.6% after lowering third quarter outlook. ALSO LOWER: GT Advanced Technologies (GTAT), down 23.3% following a Bloomberg report that it will as to wind down sapphire operations.
18:20 EDTEXASExact Sciences announces final national coverage determination for Cologuard
Subscribe for More Information
16:11 EDTAMGNAmgen blinatumomab granted priority review by FDA
Subscribe for More Information
10:00 EDTGRFSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:29 EDTGRFSGrifols downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
06:10 EDTLULUStocks with implied volatility below IV index mean; NKE LULU
Subscribe for More Information
October 8, 2014
10:20 EDTAMGNAmgen biosimilar franchise underappreciated, says Piper Jaffray
After Amgen announced positive Phase 3 results for its biosimilar Humira in psoriasis, Piper Jaffray said it believes that Amgen's overall pipeline is underappreciated since the company's biosimilar franchise is generally not included in consensus estimates. The firm views Amgen as a top large cap picks and reiterate its Overweight rating on the stock.
09:16 EDTAMGNAmgen's ABP 501 for psoriasis shows positive Phase 3 results
Subscribe for More Information
07:19 EDTAMGNCBI to hold a conference
Subscribe for More Information
07:11 EDTAMGNEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
06:00 EDTLULUStocks with implied volatility below IV index mean; ADHD LULU
Stocks with implied volatility below IV index mean; Alcobra (ADHD) 123, lululemon (LULU) 35 according to iVolatility.
05:53 EDTMNKDStocks with implied volatility movement; MNKD AFSI
Stocks with implied volatility movement; MannKind (MNKD) 85, AmTrust Financial (AFSI) 68 according to iVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use